Evaluating Immunogenicity of a TB Vaccine Candidate Through Cytokine Profiling in a Mouse Model

In 2023, Tuberculosis (TB) has reclaimed its place as the world’s leading infectious disease killer, surpassing COVID-19 and remaining a leading cause of death among people with HIV and those affected by antimicrobial resistance.

Mr. Mohd Hatimi Tukiman, a PhD candidate at Universiti Sains Malaysia, is working on a TB vaccine candidate. A crucial step in evaluating this vaccine is assessing its immunogenicity by measuring cytokine responses in a mouse model. Using mouse splenocytes, researchers can gauge the vaccine’s ability to stimulate the desired immune response. The multiplex immunoassay enables a comprehensive analysis of multiple cytokines involved, helping determine if the vaccine generates the immune profile essential for effective TB protection.

"The Luminex multiplex immunoassay, powered by xMAP® technology, allows for the simultaneous detection of up to 100 analytes in a single assay. Due to limited access to the required analyzer and lab expertise at our institute, Biomed Global’s lab service has been invaluable in providing both the resources and support we needed."